Company Overview and News
KUALA LUMPUR (Sept 24): Based on corporate announcements and news flow today, companies in focus tomorrow (Tuesday, Sept 25) may include: CIMB, Bina Puri, Heng Huat, Bintai Kinden, Mynews, MLabs, Yinson, Berjaya Media and Parkson Holdings.
PKSGF 7293 6025 3368 0175 CIMDF 5932 5657 1023 5347 PKSGY TNABY TNABF
KUALA LUMPUR (Sept 24): Bina Puri Holdings Bhd said it is cautious on the performance of its core construction business for the remaining months of its financial year ending Dec 31, 2018 (FY18), following the slew of changes to projects after the 14th general election (GE14).
IN a maiden address via email to the staff of Prasarana Malaysia Bhd, new president and CEO Datuk Mohamed Hazlan Mohamed Hussain said, “Improved passenger and operational quality as well as sound financial management of infrastructure will be the pillars of Prasarana’s excellence.”
5239 5932 8591 3204 5054
TOLL concessionaires were granted a reprieve early last week when Works Minister Baru Bian announced that the scrapping of tolls nationwide would be deferred until fiscal conditions permit.
5932 6645 7078
KUALA LUMPUR (July 12): SKH Consortium Bhd is planning to acquire a 70% stake in property development firm Rimbun Gabungan Sdn Bhd for RM12 million, from a company in which Bina Puri Holdings Bhd's founder Dr Tony Tan Cheng Kiat is a director.
KUALA LUMPUR (July 12): Based on corporate announcements and news flow today, companies in focus on Friday (July 13) may include: WCT, Lafarge Malaysia, Star Media Group, JAKS Resources, Gabungan AQRS, Atlan, Kumpulan Jetson, Nova MSC and SKH Consortium.
5932 5226 6084 3751 0026 4723 9083 1800 9679 3794
KUALA LUMPUR: Construction company Bina Puri Holdings Bhd is hoping to sustain last year’s financial performance at the very least, given that the property market remains tepid, while drastic cost cuts by the new Pakatan Harapan government have derailed several key projects.
PETALING JAYA: Property and construction outfit Bina Puri Holdings Bhd has inked a deal with Warisan Harta Sabah Sdn Bhd to develop two small hydropower sites in Kota Belud, Sabah.
5932 BSMAF 1818
KUALA LUMPUR: Scientex Bhd , Advancecon Holdings Bhd, Bina Puri Holdings Bhd , Titijaya Land Bhd and Muhibbah Engineering (M) Bhd are among the stocks to watch on Friday, according to JF Apex Research.
5239 5932 5703 2593
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...